324 related articles for article (PubMed ID: 35475634)
1. New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
Tran TT; Gomez Villegas S; Aitken SL; Butler-Wu SM; Soriano A; Werth BJ; Munita JM
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0261420. PubMed ID: 35475634
[TBL] [Abstract][Full Text] [Related]
2. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
5. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
6. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Van Bambeke F
Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
[TBL] [Abstract][Full Text] [Related]
7. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review.
Krsak M; Morrisette T; Miller M; Molina K; Huang M; Damioli L; Pisney L; Wong M; Poeschla E
Pharmacotherapy; 2020 May; 40(5):469-478. PubMed ID: 32239771
[TBL] [Abstract][Full Text] [Related]
8. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
Crotty MP; Krekel T; Burnham CA; Ritchie DJ
J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
[TBL] [Abstract][Full Text] [Related]
9. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
10. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.
Lampejo T
Int J Antimicrob Agents; 2020 Sep; 56(3):106072. PubMed ID: 32629114
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
[TBL] [Abstract][Full Text] [Related]
13. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial development in the era of emerging resistance.
Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
[TBL] [Abstract][Full Text] [Related]
15. Oritavancin: an investigational lipoglycopeptide antibiotic.
Karaoui LR; El-Lababidi R; Chahine EB
Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
[TBL] [Abstract][Full Text] [Related]
16. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
Kim A; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
18. Oritavancin: a long-acting antibacterial lipoglycopeptide.
Kaasch AJ; Seifert H
Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
[TBL] [Abstract][Full Text] [Related]
19. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections.
Cooper CC; Stein GE; Mitra S; Abubaker A; Havlichek DH
Surg Infect (Larchmt); 2021 Oct; 22(8):771-779. PubMed ID: 33835882
[No Abstract] [Full Text] [Related]
20. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.
Morrisette T; Miller MA; Montague BT; Barber GR; McQueen RB; Krsak M
J Antimicrob Chemother; 2019 Aug; 74(8):2405-2416. PubMed ID: 31322694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
